Compugen (NASDAQ:CGEN – Get Free Report) and MiMedx Group (NASDAQ:MDXG – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.
Valuation and Earnings
This table compares Compugen and MiMedx Group”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compugen | $72.76 million | 3.09 | $35.34 million | $0.38 | 6.26 |
| MiMedx Group | $418.63 million | 1.63 | $48.58 million | $0.04 | 116.75 |
Risk and Volatility
Compugen has a beta of 2.78, suggesting that its share price is 178% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
Institutional & Insider Ownership
12.2% of Compugen shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and target prices for Compugen and MiMedx Group, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compugen | 0 | 1 | 3 | 1 | 3.00 |
| MiMedx Group | 1 | 0 | 6 | 0 | 2.71 |
Compugen currently has a consensus price target of $5.00, indicating a potential upside of 110.08%. MiMedx Group has a consensus price target of $8.57, indicating a potential upside of 83.54%. Given Compugen’s stronger consensus rating and higher probable upside, equities analysts clearly believe Compugen is more favorable than MiMedx Group.
Profitability
This table compares Compugen and MiMedx Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compugen | 47.56% | 42.57% | 26.13% |
| MiMedx Group | 1.76% | 12.09% | 9.22% |
Summary
Compugen beats MiMedx Group on 10 of the 15 factors compared between the two stocks.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
About MiMedx Group
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
